Fluoroquinolones, tuberculosis, and resistance

Lancet Infectious Diseases

Volumn 3, Issue 7, 2003, Pages 432-442

  Ginsburg, Amy Sarah ^a   Grosset, Jacques H ^a   Bishai, William R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIPROFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ANAPHYLAXIS; ANOREXIA; ANTIBIOTIC RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; CHONDROPATHY; CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPOGLYCEMIA; INSOMNIA; KIDNEY DYSFUNCTION; MONOTHERAPY; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PHOTOSENSITIVITY; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SEIZURE; SIDE EFFECT; SKIN DISEASE; SYNCOPE; TENDINITIS; TENDON RUPTURE; TINNITUS; TREATMENT FAILURE; TUBERCULOSIS; VERTIGO; VOMITING;

EID: 0038788963     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00671-6     Document Type: Review

References (167)

1. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-26.0
2. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-86.
3. CDC. Reported tuberculosis in the United States, 2000. Atlanta, GA: US Depatrment of Health and Human Services, CDC, 2001.
4. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-58.
5. Chintu C, Mwinga A. An African perspective on the threat of tuberculosis and HIV/AIDS - can despair be turned to hope? Lancet 1999; 353: 997.
6. Gleissberg V. The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable? Lancet 1999; 353: 998-99.
7. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. Geneva: World Health Organization, 2001: 1294-303.
8. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367-73.
9. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
10. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-82
11. Neu HC. Clinical use of the quinolones. Lancet 1987; 2: 1319-22.
12. Landuyt HW Van, Magerman K, Gordts B. The importance of the quinolones in antibacterial therapy. J Antimicrob Chemother 1990; 26 (suppl): 1-6.
13. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002; 162: 41-47.
14. Report by IMS Health Incorporated. Fairfield, CT: IMS Health Incorporated, 2002.
15. Garcia-Rodriguez JA, Gomez Garcia AC. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32: 797-808.
16. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999; 58 (suppl): 19-22.
17. Ji B, Lounis N, Maslo C, et al. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-69.
18. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1341-44.
19. Tomioka H, Sato K, Akaki T, et al. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AMA-1 155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-04.
20. Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum ofa new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45: 437-46.
21. Ruiz-Serrano MJ, Alcala L, Martinez L, et al. In vitro activities ofsix fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-68.
22. Tomioka H, Sato K, Kajitani H, et al. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 2000; 44: 283-86.
23. Truffot-Pernot C, Ji B, Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 1991; 72: 57-64.
24. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis, Int J Antimicrob Agents 2002; 20: 464-67.
25. Hu Y, Coates AR, Mitchison DA. Sterilizing Activities of fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-57.
26. Auwera P Van der, Matsumoto T, Husson M. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother 1988; 22: 185-92.
27. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.
28. Saito H, Sato K, Tomioka H, Dekio S. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuber Lung Dis 1995; 76: 377-80.
29. Crowle AJ, Elkins N, May MH. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 1988; 137: 1141-46.
30. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities oflevofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38: 1161-64.
31. Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect ofpyrazinamide and ofloxacin within the human macrophage. Tuber Lung Dis 1996; 77: 491-95.
32. Tomioka H, Sato K, Shimizu T, Sano C. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. J Infect 2002; 44: 160-65.
33. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-25.
34. Klemens SP, Sharpe CA, Rogge MC, Cynamon MH. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38: 1476-79.
35. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 1997; 41: 607-10.
36. Miyazaki E, Miyazaki M, Chien JM, Chaisson RE. Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43: 85-89.
37. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45: 3482-86.
38. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32 (suppl): 39-46.
39. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002; 35: 1505-11.
40. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985; 28: 716-21.
41. Siefert HM, Domdey-Bette A, Henninger K, et al. Pharmacokinetics of the 8-methoxyquinulone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43 (suppl): 69-76.
42. Facts and Comparisons®. Drug facts and comparisons®. St Louis: Facts and Comparisons®, 1999.
43. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000; 30: 243-54.
44. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepatloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-03.
45. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinulone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.
46. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-51.
47. Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 901-05.
48. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45: 859-70.
49. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
50. Mitchison DA. Use of surrogate markers in clinical trials. 32nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD); Paris, France; 2001.
51. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis 1985; 131: 348-51.
52. Yew WW, Chan E, Chan CY, Cheng AF. Genotypic and phenotypic resistance of Mycobacterium tuberculosis to rifamycins and fluoroquinolones. Int J Tuberc Lung Dis 2002; 6: 936-37.
53. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992; 73: 59-67.
54. Kohno S, Koga H, Kaku M, et al. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102: 1815-18.
55. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993; 104: 1194-98.
56. Yew WW, Chau CH, Wong PC, et al. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res 1995; 21: 79-83.
57. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827-33.
58. el-Sadr WM. Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration ofshort-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26: 1148-58.
59. Telzak EE, Chirgwin KD, Nelson ET, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis 1999; 3: 337-43.
60. Yew WW, Chan CK, Chan CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-51.
61. Lubasch A, Erbes R, Mauch H, Lode H. Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J 2001; 17: 641-46.
62. Tuberculosis Research Centre (Indian Council of Medical Research), Chennai. Shortening short course chemotherapy. A randomised clinical trial for treatment ofsmear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tub 2002; 49: 27-38.
63. Yoshimatsu T, Nuermberger E, Tyagi S, et al. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002; 46: 1875-79.
64. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21: 407-21.
65. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995; 13: 343-58.
66. Burkhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990; 27: 162-70.
67. Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 1995; 28: 59-64.
68. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25: 1196-204.
69. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42: 1336-39.
70. Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24: 553-65.
71. Yew WW, Wong CF, Wong PC, et al. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin Infect Dis 1993; 17: 288-89.
72. Horn DL, Hewlett D. Jr., Alfalla C, Peterson S, Opal SM. Limited tolerance ofofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994; 330: 1241.
73. Ridzon R, Meador J, Maxwell R, et al. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997; 24: 1264-65.
74. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61; 9-18.
75. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002; 25: 111-33.
76. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213-21.
77. Gillespie SH. Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2: 265-71.
78. Dombeck M, Duch D, Dennett S, Bell L. Evaluating the implications of long-term safety and efficacy on the use of fluoroquinolones in the treatment of pulmonary tuberculosis. Research Triangle Park, NC, USA: RTI Health Solutions, 2001.
79. Richeldi L, Covi M, Ferrara G, et al. Clinical use of Levofloxacin in the long-term treatment ofdrug resistant tuberculosis. Monaldi Arch Chest Dis 2002; 57: 39-43.
80. Valerio G, Bracciale P, Manisco V, et al. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15: 66-70.
81. Management of persons exposed to multidrug resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41: 61-71.
82. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-91.
83. Crofton J, Choculet P, Maher D. Guidelines for the management of drug-resistant tuberculosis WHO/TB/96-210 (rev 1). Geneva: World Health Organization, 1997.
84. Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res 1992; 12: 173-78.
85. Yew WW, Kwan SY, Ma WK, et al. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227-36.
86. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society. Monaldi A rch Chest Dis 1994; 49: 327-45.
87. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A Decis Anal Chest 1995; 108: 712-17.
88. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Cmaj 2002; 167: 131-36.
89. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
90. Pan XS, Fisher LM. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 1129-36.
91. Varon E, Janoir C, Kitzis MD, Gutmann L. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 302-06.
92. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000; 31 (suppl): 24-28.
93. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000; 45: 583-90.
94. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 410-12.
95. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999; 2: 504-08.
96. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32 (suppl): 9-15.
97. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998; 42: 2084-88.
98. Drlica K. Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003; 3: 249-82.
99. Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 58: 773-80.
100. Alangaden GJ, Manavathu EK, Vakulenko SB, et al. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-03.
101. Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-50.
102. Kocagoz T, Hackbarth CJ, Unsal I, et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-74.
103. Williams KJ, Chan R, Piddock LJ. gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong. J Antimicrob Chemother 1996; 37: 1032-34.
104. Xu C, Kreiswirth BN, Sreevatsan S, et al. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996; 174: 1127-30.
105. Perlman DC, El Sadr WM, Heifets LB, et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11: 1473-78.
106. Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182: 517-25.
107. Takiff HE, Cimino M, Musso MC, et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996; 95: 362-66.
108. Cambau E, Jarlier V. Resistance to quinolones in mycobacteria. Res Microbiol 1996; 147: 52-59.
109. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994; 123: 11-18.
110. Liu J, Takiff H, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Baceriol 1996; 178: 3791-95.
111. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-35.
112. Piddock LJ, Johnson M, Ricci V, Hill SL. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998; 42: 2956-60.
113. Banerjee SK, Bhatt K, Rana S, et al. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem Biophys Res Commun 1996; 226: 362-68.
114. Bryan LE, Bedard J. Impermeability to quinolones in gram-positive and gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1991; 10: 232-39.
115. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992; 36: 695-703.
116. Montero C, Mateu G, Rodriguez R, Takiff H. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 2001; 45: 3387-92.
117. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997; 24 (suppl): 67-73.
118. Richard P, Delangle MH, Merrien D, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association. J Clin Infect Dis 1994; 19: 54-59.
119. Lee AS, Tang LL, Lim IH, Wong SY. Characterization ofpyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis 2002; 6: 48-51.
120. Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182: 517-25.
121. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 (suppl): 147-56.
122. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 2002; 185: 561-65.
123. Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1604-13.
124. Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000; 44: 3337-43.
125. Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2581-84.
126. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337-41.
127. Wise R, Brenwald N, Gill M, Fraise A. Streptococcus pneumoniae resistance to fluoroquinolones. Lancet 1996; 348: 1660.
128. Appelbaum PC. Resistance among Streptococcus pneumoniae implications for drug selection. Clin Infect Dis 2002; 34: 1613-20.
129. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 50: 800-04.
130. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition oflevofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701-07.
131. Richard P, Delangle MH, Raffi F, et al. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001; 32: 162-66.
132. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-88.
133. Levy SB. Multidrug resistance - a sign of the times. N Engl J Med 1998; 338: 1376-78.
134. Luo N, Sahin O, Lin J, et al. In vivo selection of campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 2003; 47: 390-94.
135. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 151: 352-56.
136. Canetti G. The J. Amberson Lecture. Present aspects of bacterial resistance in tuberculosis. Amer Rev Repir Dis 1965; 92: 687-703.
137. Collins CH, Uttley AH. In-vitro susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother 1985; 16: 575-80.
138. Bozeman L, Burman W, Metchock B, et al. Fluoroquinolone susceptibility among selected Mycobacterium tuberculosis isolates from the United States and Canada. Am J Respir Crit Care Med 2002; 165 (suppl): A18.
139. Tupasi TE. MDR in the Philippines. 4th World Congress on Tuberculosis; Washington, DC; 2002.
140. Tupasi TE. Utility of fluoroquinolones in multidrug-resistant tuberculosis (MDR-TB) - a balanced view? In reply. Int J Tuberc Lung Dis 2002; 6: 174-75.
141. The Philippine clinical practice guidelines on the diagnosis, empiric management and prevention of community acquired pneumonia in immunocompetent adults. Report of the Task Force on Community Acquired Pneumonia. Manila: The Philippine Practice Guideline Group-Infectious Diseases, 1998, 1: 1-29.
142. Rastogi N, Ross BC, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Effect Dis 1992; 11: 901-07.
143. Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-50.
144. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-26.
145. Gordin FM, Nelson ET, Matts JP, et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 154: 1478-83.
146. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-37.
147. Asch S, Knowles L, Rai A, et al. Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis. Am J Respir Crit Care Med 1996; 153: 1708-10.
148. Spellman CW, Matty KJ, Weis SE. A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. AIDS 1998; 12: 191-95.
149. Churchyard GJ, Corbett EL, Kleinschmidt I, et al. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 2000; 4: 433-40.
150. Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-97.
151. Law KF, Jagirdar J, Weiden MD, et al. Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med 1996; 153: 1377-84.
152. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-35.
153. Goodwin SD, Gallis HA, Chow AT, et al. Pharmacokinetics and safety oflevofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994; 38: 799-804.
154. Owens RC. Jr., Patel KB, Banevicius MA, Quintiliani R, Nightingale CH, Nicolau DP. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Antimicrob Agents Chemother 1997; 41: 1508-11.
155. Dylewski J, Thibert L. Failure of tuberculosis chemotherapy in a human immunodeficiency virus-infected patient. J Infect Dis 1990; 162: 778-79.
156. Nolan CM, Williams DL, Cave MD, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995; 152: 1067-71.
157. Bradford WZ, Martin JN, Reingold AL, et al. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348: 928-31.
158. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-84.
159. Lutfey M. Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153: 837-40.
160. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-94.
161. Bishai WR, Graham NM, Harrington S, et al. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996; 334: 1573-76.
162. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25: 1465-67.
163. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-47.
164. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51: 214-15.
165. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-34.
166. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-30.
167. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-14.